Genetic Signatures in the Treatment of Stroke.

Genetic Signatures in the Treatment of Stroke. Curr Pharm Des. 2014 Aug 26; Authors: Munshia A, Sharma V Abstract Stroke is the fourth leading cause of mortality and neurological disability. It is caused by an intricate interplay of environmental and genetic factors. Genes not only influence susceptibility to stroke but have also been found to alter the response to pharmacological agents and may also influence the clinical outcome of the disease. Current treatment strategies for stroke include tissue plasminogen activator, antiplatelet agents and lipid lowering drugs. These act via diverse mechanisms of actions and are centered around the management of modifiable risk factors to prevent the recurrent stroke events. However, a significant number of patients experience poor clinical outcome due to recurrent stroke events and drug induced adverse reactions. Therefore, accurate risk management and targeted prevention strategies remain yet to be explored at the level of individual patients with stroke. Pharmacogenetic based research studies have identified the relation between genetic factors and inter-individual variability towards drug treatment. Several single nucleotide polymorphisms in genes encoding for metabolizers, transporters and target receptors have been reported to influence the pharmacokinetics and pharmacodynamics of drugs used in the treatment of stroke. Many candidate gene studies have investigated the role of genetic var...
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Tags: Curr Pharm Des Source Type: research